Digoxin's Role in Heart Failure Management
Introduction to Digoxin's Mechanism and Clinical Applications
- The American Heart Association recommends digoxin as a second or third-line therapy for symptomatic heart failure with reduced ejection fraction (HFrEF), with its main benefit being reduction in hospitalizations rather than mortality improvement 1
- Digoxin inhibits sodium-potassium adenosine triphosphatase (Na-K ATPase) in cardiac cells, resulting in increased intracellular calcium and enhanced myocardial contractility (positive inotropic effect) 2
Clinical Applications and Efficacy
- The American College of Cardiology suggests that digoxin should be considered in patients with persistent symptoms despite therapy with diuretics, ACE inhibitors/ARBs, and beta-blockers, with a strength of evidence level of B 3, 1
- Digoxin has been shown to improve symptoms, quality of life, and exercise tolerance in patients with mild to moderate heart failure, with a moderate level of evidence 3, 1
- The Digitalis Investigation Group (DIG) trial found that digoxin had no effect on mortality but modestly reduced the combined risk of death and hospitalization, with a high level of evidence 3, 1
Dosing and Monitoring
- The recommended dosage is 0.125-0.25 mg daily for most patients, with a target serum concentration of 0.5-0.9 ng/mL, particularly in older adults 7
- Serum levels above 2 ng/mL are commonly associated with toxicity, with a high level of evidence 4, 7
Safety Concerns and Limitations
- The European Society of Cardiology notes that digoxin has a narrow therapeutic index and risk of toxicity, with a high level of evidence 4, 7
- Post-hoc analyses of the DIG trial suggested women may not benefit from digoxin therapy and may be at increased risk for death, with a moderate level of evidence 4, 8
- Digoxin should be used with caution or not at all in post-MI patients, particularly those with ongoing ischemia, with a moderate level of evidence 5